Notes: *: p <.05; chi² test, t-test for independent groups IQR - interquartile range, Md - median
Figure 1:
Map of Bavaria with location of centers contributing to the survey (red dots) and COVID-19 prevalence until July 2020 (color coded by county). Number for overall, negatively and positively tested children are given in the circle chart
Figure 2:
Comparison between the N protein directed Elecsys Anti-SARS-CoV-2 assay (total Ig) and the S protein directed in-house SARS-CoV-2 assay detecting IgG (IgG) in the total study population (N=2832). Strong dotted lines represent the assay cutoff values, ±10% borderline intervals (gray areas). Signal-to-cutoff (S/Co) ratios are given for both assays.
Figure 3:
Study flowchart (upper panel) and findings from the follow-up of SARS-CoV-2 seropositive children for PMIS symptoms in the CoKiBa study (lower panel)
Legend: * only those 52 individuals who actively contacted their pediatrician could be included into the follow up. Due to the anonymous design of the study no reminder was possible. ** Individuals could report more than one symptom. AB is antibody, LDH is lactate dehydrogenase
Figure 4:
Neutralizing and S-protein specific binding antibody titer analysis of children from follow up with N-specific signal S/Co>100
Legend: A. Correlation of N-specific antibody signal (Elecsys, S/Co) with neutralizing antibody titers. B. Correlation of S-protein ELISA binding antibody titers (S/Co) with neutralizing antibody titers. C. Dotplot representation of the neutralizing antibody titers of all children examined in the follow up study, visualizing symptomatic children by dot colour and shape. D . Pie chart distribution of symptomatic children grouped according to neutralizing antibody titer. E. Comparison of the neutralization capacity of symptomatic and asymptomatic children.